Systemic Lupus Erythematosus

Anti-Telomere IgG ELISA, 96 wells, Cat. No. 604 010*

Anti-Telomere IgG binding based on the Double-Stranded Telomeric DNA Recognition.

Systemic Lupus Erythematosus (SLE) is a typical autoimmune disease, which affects almost every organ of the body and which, with its various symptoms, resembles rheumatic diseases. Although SLE mainly affects women, also men and even children can be affected. Common disorders related to SLE are malar rash, discoid rash, sensitivity to sunlight, oral ulcers, arthritis, serositis, kidney problems (e.g. proteinuria), problems related with the central nervous system, blood circulation, the immune system, as well as antinuclear antibodies. The presence of multiple antibodies, especially IgG –class antibodies directed against native telomeric double-stranded DNA (anti–Telomere), is one of the most specific tests for SLE. Since the level of circulating antibodies to double-stranded DNA has important diagnostic and therapeutic implications in the treatment of patients with SLE, many techniques have been developed to measure these antibodies.

Telomeres, which represent 0.15 % of the human genome, are highly repetitive sequences of the DNA (TTAGGG/CCCTAA)n at the end of eukaryotic chromosomes. Human antibodies against telomeric DNA are very specific and sensitive test for SLE1.

The anti–Telomere IgG antibody test of Biohit measures by a sensitive and specific enzyme immunoassay procedure (ELISA) telomere IgG antibodies in the serum of an SLE patient. Unlike in the conventional DNA antibody tests, which use purified calf thymus DNA as capture antigens for autoantibodies, the newly developed Biohit anti–telomere antibody assay is based on the use of double –stranded telomeric DNA as the capture antigen for the binding of antibodies. The Biohit anti–telomere antibody assay has the following advantages over the conventional anti–dsDNA tests in SLE screening:

• High affinity to anti–telomere IgG 
• Increased specificity (human DNA sequence as a capture antigen)
• Reduced background, no crossreactions
• High reproducibility
• Easily automated

References:

1. Salonen EM, Miettinen A, Walle TK, Koskenmies S, Kere J, Julkunen H. Anti-telomere antibodies in systemic lupus erythematosus (SLE): a comparison with five antinuclear antibody assays in 430 patietns with SLE and other rheumatic diseases. Ann Rheum Dis 2004; 63: 250-254.
2. Wallace DJ, Salonen E-M, Avaniss-Aghajani E, Morris R, Metzger AL, Pashinian N, Lupus 2000; 9:328-332. 
3. Patents: Anti-DNA Antibody Detection Involving Telomeric DNA Sequence Recognition and Binding. US 5,700,641, EP 0812421, FI 100556, AUS 720912, NZ 301725
   

*For research use only. Not for diagnostics use.